In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 6, 2009, Pages

  Chen, Yen Hsu ^a   Liu, Chia Ying ^b   Lu, Jang Jih ^c   King, Chi Hsin R ^d   Hsueh, Po Ren ^e  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TaiGen Biotechnology Co Ltd   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Daptomycin non susceptible; Gemifloxacin; Levofloxacin; Moxifloxacin; Vancomycin intermediate

Indexed keywords

CIPROFLOXACIN; DAPTOMYCIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NEMONOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TG 873870; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; QUINOLONE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENCY; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TAIWAN; VANCOMYCIN RESISTANT ENTEROCOCCUS; AMINO ACID SUBSTITUTION; DRUG EFFECT; GENETICS; GRAM POSITIVE INFECTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MISSENSE MUTATION;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; QUINOLONES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TAIWAN;

EID: 76249084411     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp370     Document Type: Article

References (10)

1. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N Engl J Med 2009; 360: 439-43.
2. Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2007; 45 Suppl 3: S184-90.
3. Arjona A. Nemonoxacin. Drugs of the Future 2009; 34: 196-203.
4. Tan CK, Lai CC, Liao CH et al. Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 2009; 64: 428-9.
5. Lai CC, Tan CK, Lin SH et al. Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species. J Antimicrob Chemother 2009; 64: 73-8.
6. Hsieh YC, Chang LY, Huang YC et al. Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan. Clin Microbiol Infect 2009; doi:10.111/j1469-0691.2009.02951.
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement M100-S18. CLSI, Wayne, PA, USA, 2008.
8. European Committee on Antimicrobial Susceptibility Testing. Fluoroquinolones - EUCAST Clinical MIC Breakpoints. http://www.srga.org/eucastwt/mictab/micquinolones.htm (7 April 2009, date last accessed).
9. Lin L, Chang LW, Tsai CY et al. A dose-escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum non-fluorinated quinolone, in healthy volunteers. Antimicrob Agents Chemother 2009; in press.
10. Adam HJ, Laing NM, King CR et al. In vitro activity of nemonoxacin, a novel non-fluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother 2009; doi:10.1128/AAC.00078-09.